NCT04287179 - SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes | Biotech Hunter

Timeline

Start Date

March 9, 2020

Primary Completion Date

November 16, 2020

Study Completion Date

January 25, 2021

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.

Trial Locations (25)

1090

Novo Nordisk Investigational Site, Vienna

1130

Novo Nordisk Investigational Site, Vienna

2000

Novo Nordisk Investigational Site, Stockerau

8036

Novo Nordisk Investigational Site, Graz

12206

Novo Nordisk Investigational Site, Albany

14224

Novo Nordisk Investigational Site, West Seneca

15100

Novo Nordisk Investigational Site, Lahti

21200

Novo Nordisk Investigational Site, Raisio

40100

Novo Nordisk Investigational Site, Jyväskylä

46260

Novo Nordisk Investigational Site, Indianapolis

48098

Novo Nordisk Investigational Site, Troy

60220

Novo Nordisk Investigational Site, Seinäjoki

70100

Novo Nordisk Investigational Site, Kuopio

77478

Novo Nordisk Investigational Site, Sugar Land

78681

Novo Nordisk Investigational Site, Round Rock

90620

Novo Nordisk Investigational Site, Buena Park

93720

Novo Nordisk Investigational Site, Fresno

94598

Novo Nordisk Investigational Site, Walnut Creek

95148

Novo Nordisk Investigational Site, San Jose

96814

Novo Nordisk Investigational Site, Honolulu

06708

Novo Nordisk Investigational Site, Waterbury

83404-7596

Novo Nordisk Investigational Site, Idaho Falls

75390-9302

Novo Nordisk Investigational Site, Dallas

413 45

Novo Nordisk Investigational Site, Gothenburg

205 02

Novo Nordisk Investigational Site, Malmo